Once-Weekly Semaglutide 2.4 Mg Improved Glucose Metabolism And Prediabetes In Adults With Overweight Or Obesity In The Step 1 Trial

Semaglutide 2.4 mg demonstrated 14.9% body weight (BW) loss in adults with overweight/obesity in STEP 1. We evaluated effects on glucose metabolism in subjects with prediabetes at baseline (BL). Subjects (N=1,961) were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, plus lifestyle intervention, for 68 weeks. Post-hoc analyses included change from BL to week 68 in glycemic status (normoglycemia, prediabetes or type 2 diabetes; all investigator assessed), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG) and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).